Results 31 to 40 of about 3,216,105 (293)

CARDIOVASCULAR DISEASES IN RHEUMATOID ARTHRITIS: LATEST DATA

Научно-практическая ревматология, 2016
The paper gives the latest data on the impact of traditional cardiovascular risk factors, chronic inflammation, antirheumatic therapy (disease-modifying antirheumatic drugs and biological agents) on the cardiovascular system.
T. V. Popkova, D. S. Novikova, E. L. Nasonov   +2 more
doaj   +1 more source

Rheumatoid arthritis [PDF]

, 2016
Rheumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage as well as disability. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterised risk factors for poor ...
Aletaha, Daniel, McInnes, Iain B., Smolen, Josef S.   +2 more
core   +1 more source

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. [PDF]

, 2019
ObjectiveTo evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoid arthritis (RA).MethodsThis was a multi-centre ...
Genant, Harry K, Nitta, Takaya, Okubo, Naoki, Soen, Satoshi, Takeuchi, Tsutomu, Tanaka, Sakae, Tanaka, Yoshiya, van der Heijde, Désirée, Yamanaka, Hisashi, Yoneda, Toshiyuki   +9 more
core   +2 more sources

Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. [PDF]

, 2009
ObjectiveC-reactive protein (CRP) levels>3 mg/L and>10 mg/L are associated with high and very high cardiovascular risk, respectively, in the general population.
Graf, Jonathan, Grunfeld, Carl, Imboden, John, Scherzer, Rebecca   +3 more
core   +8 more sources

Synergistic drug combinations from electronic health records and gene expression. [PDF]

, 2016
ObjectiveUsing electronic health records (EHRs) and biomolecular data, we sought to discover drug pairs with synergistic repurposing potential. EHRs provide real-world treatment and outcome patterns, while complementary biomolecular data, including ...
Chen, William, Daugherty, Aaron C, Desai, Manisha, Farrington, Carl, Gomez, Scarlett L, Hastie, Trevor, Kenkare, Pragati, Kurian, Allison W, Lim, Michael, Low, Yen S, Mathur, Maya, Radin, Andrew A, Schroeder, Elizabeth A, Seto, Tina, Shah, Nigam H, Sirota, Marina, Sledge, George W, Thompson, Caroline A, Weber, Susan, Yu, Peter P   +19 more
core   +2 more sources

Treatment recommendations for psoriatic arthritis [PDF]

, 2008
Objective: To develop comprehensive recommendations for the treatment of the various clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a systematic review of the literature and from consensus opinion.
Boehncke, Wolf-Henning, Fiorentino, David, FitzGerald, Oliver, Gladman, Dafna D., Gottlieb, Alice B., Helliwell, Philip, Kavanaugh, Arthur, McHugh, Neil J., Mease, Philip J., Nash, Peter, Qureshi, Abrar A., Ritchlin, Christopher T., Soriano, Enrique R., Taylor, William J., Vlam, Kurt de   +14 more
core   +3 more sources

What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis [PDF]

, 2020
Introduction: To determine patient and rheumatologist preferences for rheumatoid arthritis (RA) treatment attributes in Spain and to evaluate their attitude towards shared decision-making (SDM).
Comellas, M., Dilla, T., Díaz Torne, César, Díaz, S., Inciarte-Mundo, J., Ivorra-Cortés, J., Lizán, L., Prades, M., Sacristán, J.A., Universitat Autònoma de Barcelona, Urruticoechea-Arana, A.   +10 more
core   +2 more sources

Collagenase production by human mononuclear cells in culture: inhibition by gold containing compounds and other antirheumatic agents.

Annals of the Rheumatic Diseases, 1986
Akio Ohta, James S. Louie, Jouni Uitto
openalex   +2 more sources

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis

Arthritis Research & Therapy, 2017
Background Biologic disease-modifying antirheumatic drugs (DMARDs) are increasingly used for rheumatoid arthritis (RA) treatment. However, little is known based on contemporary data about the factors associated with DMARDs and patterns of use of biologic
Yinzhu Jin, Rishi J. Desai, Jun Liu, Nam-Kyong Choi, Seoyoung C. Kim   +4 more
doaj   +1 more source

REVIEW OF THE 2017 AMERICAN COLLEGE OF RHEUMATOLOGY/AMERICAN ASSOCIATION OF HIP AND KNEE SURGEONS GUIDELINES FOR THE PERIOPERATIVE MANAGEMENT AND ANTIRHEUMATIC THERAPY OF PATIENTS WITH RHEUMATIC DISEASES BEFORE TOTAL KNEE AND HIP ARTHROPLASTY

Научно-практическая ревматология, 2018
The article presents the guidelines developed by the American College of Rheumatology and the American Association of Hip and Knee Surgeons for the perioperative management of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic ...
V. N. Amirdzhanova, A. E. Karateev, E. Yu. Pogozheva   +2 more
doaj   +1 more source